Depo-Provera CI can cause serious side effects, including: Effect on the bones: See "What is the most important information I should know about Depo-Provera CI?"
Additional serious risks include: Acute pancreatitis severe, persistent abdominal pain radiating to the back requires immediate medical attention Gallbladder disease rapid weight loss from any cause increases gallstone risk Acute kidney injury secondary to dehydration from vomiting/diarrhoea Hypoglycaemia increased risk when combined with insulin or sulfonylureas Aspiration risk during surgery delayed gastric emptying may require pre-operative fasting adjustments Contraindications Who Should Not Take Foundayo Orforglipron is contraindicated in patients with: Personal or family history of medullary thyroid carcinoma (MTC) Multiple Endocrine Neoplasia syndrome type 2 (MEN2) Pregnancy or planned pregnancy (discontinue at least 2 months before planned conception) Severe gastrointestinal disease including gastroparesis History of pancreatitis Type 1 diabetes Prior serious hypersensitivity reactions to any GLP-1 receptor agonist Critically, orforglipron should not be combined with other GLP-1 receptor agonists including Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, or Rybelsus
Its Phase 2/3 LIFT-AD Alzheimer's trial failed its primary endpoint in September 2024 (GST 0.08, P=.70)
Authorization criteria include a body mass index over 40 or a body mass index over 35 with additional risk factors such as diabetes or high blood pressure as well as a recommended six-month trial of caloric restriction and increased exercise
His job was to design and oversee clinical trials for the pill and then step back
